1. Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS. (May 2023) Authors: Garcia-Manero, G.; Bachiashvili, K.; Amin, H.; Traer, E.; Pollyea, D.; Sallman, D.; Al-Kali, A.; Cripe, L.; Berdeja, J.; Griffiths, E.; Mohan, S.; Vachhani, P.; Sano, Y.; Oganesian, A.; Keer, H.; Yacoub, A. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS. (May 2023) Authors: Garcia-Manero, G.; Bachiashvili, K.; Griffiths, E.; Traer, E.; Saini, L.; Amin, H.; Zeidan, A.; Mohan, S.; Lübbert, M.; Maness, L.; Foran, J.; Selleslag, D.; Xicoy, B.; Pollyea, D.; Sallman, D.; Al-Kali, A.; Berdeja, J.; Al-Ali, H.; Zhu, N.; Lopez, P. Font Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗